Literature DB >> 16932456

A serum potassium level above 10 mmol/l in a patient predisposed to hypokalemia.

David R Phillips1, Kashif I Ahmad, Sarah J Waller, Peter Meisner, Fiona E Karet.   

Abstract

BACKGROUND: A 58-year-old man, previously diagnosed with Bartter's syndrome, presented with a short history of vomiting, diarrhea and weakness. He had severe hyperkalemia (serum potassium levels >10 mmol/l), which was successfully managed. Post hoc investigation suggested that the patient had Gitelman's rather than Bartter's syndrome. INVESTIGATIONS: Physical examination, urine and blood analyses, chest radiography, electrocardiogram, renal ultrasound, and genetic analysis focusing on the SLC12A3 gene, which encodes the thiazide-sensitive Na/Cl cotransporter. DIAGNOSIS: Gitelman's syndrome and hyperkalemia secondary to acute renal failure plus exogenous potassium supplementation. MANAGEMENT: Intravenous calcium gluconate, insulin and dextrose administration. Temporary continuous venovenous hemodiafiltration. Genetic confirmation of the underlying molecular defect. Long-term treatment for Gitelman's syndrome with oral potassium and magnesium supplements and epithelial sodium channel-blocking drugs. Review of patient education regarding renal salt-wasting syndromes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16932456     DOI: 10.1038/ncpneph0201

Source DB:  PubMed          Journal:  Nat Clin Pract Nephrol        ISSN: 1745-8323


  4 in total

Review 1.  Gitelman's syndrome: towards genotype-phenotype correlations?

Authors:  Eva Riveira-Munoz; Qing Chang; René J Bindels; Olivier Devuyst
Journal:  Pediatr Nephrol       Date:  2006-10-24       Impact factor: 3.714

Review 2.  Hypokalemic rhabdomyolysis in congenital tubular disorders: a case series and a systematic review.

Authors:  Rodo O von Vigier; Maria Teresa Ortisi; Angela La Manna; Mario G Bianchetti; Alberto Bettinelli
Journal:  Pediatr Nephrol       Date:  2009-12-22       Impact factor: 3.714

Review 3.  Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Authors:  Hannsjörg W Seyberth; Karl P Schlingmann
Journal:  Pediatr Nephrol       Date:  2011-04-19       Impact factor: 3.714

4.  Gluconate suppresses seizure activity in developing brains by inhibiting CLC-3 chloride channels.

Authors:  Zheng Wu; Qingwei Huo; Liang Ren; Fengping Dong; Mengyang Feng; Yue Wang; Yuting Bai; Bernhard Lüscher; Sheng-Tian Li; Guan-Lei Wang; Cheng Long; Yun Wang; Gangyi Wu; Gong Chen
Journal:  Mol Brain       Date:  2019-05-15       Impact factor: 4.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.